A factory can have every machine it needs and still stop for want of one small part. In the cells of a person with PMM2-CDG, the missing part is mannose-1-phosphate. An enzyme called PMM2 ordinarily makes it. When inherited mutations reduce that enzyme's activity, the cell struggles to build the sugar chains that help many proteins take their proper shape and perform their jobs. Glycomine has spent a decade on an almost impolite question: why fix the machine if you can deliver the part?
- Glycomine develops experimental treatments for rare metabolic diseases; GLM101 is its lead drug.
- GLM101 packages mannose-1-phosphate for weekly intravenous delivery to bypass the faulty PMM2 enzyme.
- An open-label study showed improvement in ataxia. A randomized, placebo-controlled trial enrolled 43 people to test that signal.
- The company has announced $195 million in financing. It has no approved product.
The disease name is a mouthful - phosphomannomutase 2 congenital disorder of glycosylation - but the consequence is easy to recognize. Glycosylation attaches sugar chains to proteins. With too little of the required building block, many tissues can be affected. The disorder can bring poor coordination, developmental challenges, liver and heart problems, and other serious symptoms. Glycomine estimates about 14,000 people with PMM2-CDG in the United States and Europe, though far fewer have been diagnosed. For a family living with it, “rare” is an epidemiologist's word, not a description of how often it enters the room.
The shortest route around a broken enzyme
The familiar response to an enzyme deficiency is to replace the enzyme. Glycomine chose the product of the enzyme instead. PMM2 converts mannose-6-phosphate into mannose-1-phosphate. GLM101 is designed to supply that second molecule directly, past the genetic block. In principle, this could work across different PMM2 mutations because it addresses a shared downstream shortage. That is the company's scientific distinction, and still a clinical hypothesis.
THE DETOUR / Glycomine sends the missing ingredient around the stalled enzymatic step.
There was a catch before anyone could ask whether the medicine helped a patient. Unprotected mannose-1-phosphate is broken down rapidly in the body; CEO Steven Axon told MedCity News its life there is about five minutes. Glycomine put the molecule inside a lipid carrier. Axon said that formulation extended circulating half-life to about 80 hours. The current regimen is a weekly intravenous infusion. The carrier is not decorative packaging. It is the part that makes the premise testable.
“We deliver that weekly because a lot of the proteins that we’re interested in, they turn over in days.”Steven Axon, CEO, speaking to MedCity News in 2025
The intended users are people with PMM2-CDG, working with specialist clinicians. Today they are trial participants, not purchasers: GLM101 remains investigational. Glycomine operates as a venture-funded drug developer, spending capital to establish safety, efficacy, manufacturing and a regulatory path. There is no public price for the treatment because there is no approved treatment to sell. The tangible price so far is the financing committed to finding out whether it works.
Before the trial, the ruler
For a disorder this varied, picking a drug target is only half the work. One must decide what change to measure, and how to distinguish it from the ordinary course of the disease. Glycomine ran a natural history study enrolling 139 patients across 11 sites in the United States and Europe. That effort examined clinical measures and biomarkers and helped inform the choice of ataxia - impaired coordination - as a trial endpoint. More than 90% of people with PMM2-CDG have ataxia, according to the company. A measurement this common can make a small trial more informative.
The early clinical signal was striking enough to attract both money and scrutiny. In a Phase 2 open-label study, nine adolescents and adults had an average 11.9-point improvement on the International Cooperative Ataxia Rating Scale after 24 weeks of GLM101, according to Glycomine. Everyone knew treatment was being given. That is useful evidence for designing the next study, but it cannot by itself settle how much improvement came from the drug. The company moved to a randomized, double-blind, placebo-controlled trial called POLAR.
POLAR enrolled children and adults aged 4 to 47 at sites across the United States, United Kingdom and Europe. Its primary question is whether ataxia changes more after 24 weeks on GLM101 than on placebo. After that blinded part, all participants can receive the drug through week 48. Enrollment finished in April 2026. Glycomine expects topline data in the fourth quarter of 2026. Small numbers are unavoidable in this field; disciplined comparison is therefore particularly valuable.
What $195 million bought
The financing tells a story of progressively harder questions. Glycomine's 2016 Series A raised $12 million, with support from Sanderling Ventures, Chiesi Ventures, individuals and patients. That money was aimed at work before human trials. The Series B ultimately reached $68 million: $33 million announced in 2019 and another $35 million in 2021. It carried GLM101 into clinical testing. In April 2025, a $115 million Series C financed the controlled POLAR study. Add the announced rounds and the bill is $195 million. It is capital raised, not a published accounting of research costs.
The 2016 announcement also mentioned an enzyme replacement program for NGLY1 deficiency. Glycomine's public clinical story today, however, centers on GLM101. The broader platform idea is to deliver substrates, enzymes or proteins to the cells where a pathway has failed. The company has not named another clinical candidate with comparable public detail. That makes GLM101 both the example and the test of the platform's promise.
The company sits in a peculiar corner of biotechnology. Conventional supportive care treats symptoms; GLM101 aims at the biochemical cause. Gene therapy would aim to alter the underlying genetic problem; this candidate instead provides a missing product repeatedly. Weekly infusions are a considerable burden, especially for children and their families, but the approach may also allow dose adjustment. Its practical value depends on a net benefit that patients can feel and clinicians can measure. The placebo comparison is built to answer exactly that.
A playbook worth borrowing
Find the common bottleneck beneath diverse mutations. Test whether its missing product can be carried into the right cells. Study the untreated disease long enough to choose a useful endpoint. Then expose the encouraging early result to a blinded comparison. Glycomine's sequence is portable; its biology is not.
September brought another milestone. The FDA granted GLM101 Breakthrough Therapy designation on the strength of preliminary Phase 2a evidence. That can mean closer contact with regulators and a more efficient development conversation. It is not an approval, nor a verdict on POLAR. Glycomine already had orphan drug designations in the United States and Europe, plus U.S. Rare Pediatric Disease and Fast Track designations. Each changes the route through drug development; none replaces the destination.
For a company named after sugar, the central wager is unusually unsweetened. If the randomized trial confirms a meaningful improvement in coordination, GLM101 may offer a treatment where none is approved. If the effect fades against placebo, an elegant mechanism will remain an elegant mechanism. Either result will be more useful than a slogan. Forty-three people have already done the difficult part of making the question answerable.